The U.S. Food & Drug Administration (FDA) has cleared Thermo Fisher Scientific's ImmunoCAP Specific IgE (sIgE) Allergen Components for use in in vitro diagnostic testing for wheat and sesame allergies. These cutting-edge blood tests, which are also anticipated to be made available countrywide, can serve as a diagnostic tool for physicians and other healthcare professionals by assisting in the identification of wheat and sesame allergies in patients who may experience a severe allergic reaction.
Leading provider of immunology and infectious disease testing, Eurofins Viracor, officially opened its new, large laboratory in Lenexa, Kansas, today. With 215 current employees and 235 newly created roles, the 110,000 square foot, state-of-the-art facility will employ 450 people and provide additional capacity to support development in biopharma and transplant diagnostic testing services.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5551
Published Date: Jan 22, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The major factors driving the growth of the market are a surge in pollution levels, growing utilization of mHealth, and rising prevalence of food allergies.
The market size of IgE allergy blood tests is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024-2036.
The major players in the market are Thermo Fisher Scientific, Inc., Eurofins Viracor, Neogen Corporation, Omega Diagnostics PLC and others.
The diagnostics laboratories segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.